<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03027856</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-194-16</org_study_id>
    <nct_id>NCT03027856</nct_id>
  </id_info>
  <brief_title>The BIFSORB Pilot Study II</brief_title>
  <acronym>BIFSORB P-II</acronym>
  <official_title>A Sirolimus Eluting Bioresorbable Magnesium Stent for Treatment of Coronary Bifurcation Lesions - The BIFSORB Pilot Study II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital Skejby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital Skejby</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the feasibility and safety of the Magmaris BRS
      for treatment of coronary bifurcation lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bioresorbable stents are promising in treatment of coronary artery disease. The concept of
      bifurcation treatment using BRS is particular appealing as struts covering the side branch
      ostium may resorb over time.

      The aim of this study is to investigate the feasibility and safety of the Magmaris BRS for
      treatment of coronary bifurcation lesions.

      Hypothesis: treatment of coronary bifurcation lesions using the Magmaris BRS is safe and
      feasible.

      Methods:

      The study is a proof-of-concept, prospective, single arm study with inclusion of 20 patients.
      Planned 1-and 12-month follow-up by optical coherence tomography (OCT) and follow-up for
      clinical endpoints until 5 years.

      Written informed consent is required before the procedure is performed. Eligible patients
      with a bifurcation lesion are treated by the provisional technique with mandatory jailing of
      the side branch and provisional opening of side branch ostium by the mini-kiss technique in
      case of severe pinching or TIMI-flow less than III. Proximal post-dilatation is mandatory. No
      dilatation beyond the expansion limits of the stent.

      At baseline, the target lesion is assessed by OCT before, during and after implantation of
      the Magmaris BRS. OCT assessment is performed again at 1- and 12-month follow-up, or before
      if the patient is readmitted with a possible target lesion failure.

      The operator is not blinded to the OCT images as pre-PCI images should be used for sizing and
      positioning of the stent, and procedural OCT images are used to optimize stent implantation
      before performing final OCT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death</measure>
    <time_frame>1 month</time_frame>
    <description>Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Index of adverse vessel wall features by OCT</measure>
    <time_frame>1 month</time_frame>
    <description>Index based on: side branch ostial area late loss, strut fracture, uncovered non-side branch apposed stent struts, uncovered stent struts in front of side branch, uncovered stent struts on acquired or persistent malapposed struts, persistent malapposition, max neointimal thickness/area stenosis, cumulated extra stent lumen gain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Acute malapposition</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Acquired malapposition</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Persistent malapposition</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Coverage of jailing struts</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Extra stent lumen (including evaginations)</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Late stent recoil</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Stent fracture</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Single end attached protruding (floating) struts or neointimal tissue resembling struts</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Ostial strut loss</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Mean neointimal thickness</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Stent strut coverage</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Minimal luminal area in segmental analysis</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Minimal stent area in segmental analysis</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Minimum stent expansion area %</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Segmental area stenosis</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Healing above calcified plaque</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Healing above lipid plaque</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Acute thrombus on struts</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Late thrombus on struts</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Acute expansion</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured in segments with: 1) calcified plaque, 2) lipid plaque, 3) area after predilatation &lt; 30% of reference area, 4) stenosed segments (&gt;50% area stenosis) with no dissections after predilatation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical coherence tomography endpoint: Late recoil</measure>
    <time_frame>1 month</time_frame>
    <description>Measured in segments with: 1) calcified plaque, 2) lipid plaque, 3) area after predilatation &lt; 30% of reference area, 4) stenosed segments (&gt;50% area stenosis) with no dissections after predilatation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Ostial side branch area stenosis</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Ostial side branch acute gain after main vessel stenting</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Ostial side branch late loss</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Ostial distal main vessel area stenosis</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Ostial distal main vessel acute gain after main vessel stenting</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Ostial distal main vessel late loss</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Proximal main vessel area stenosis</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Proximal main vessel acute gain after main vessel stenting</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Proximal main vessel late loss</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoint: Minimal luminal area of all segments</measure>
    <time_frame>Baseline and 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural endpoint: Procedure time</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural endpoint: Contrast use in mL</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural endpoint: Fluoroscopy time</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death</measure>
    <time_frame>6 months</time_frame>
    <description>Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death</measure>
    <time_frame>24 months</time_frame>
    <description>Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death</measure>
    <time_frame>60 months</time_frame>
    <description>Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical endpoint: myocardial infarction</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical endpoint: target lesion failure</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical endpoint: target lesion revascularization</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical endpoint: stent thrombosis</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical endpoint: cardiac death</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical endpoint: non-cardiac death</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Magmaris</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of sirolimus eluting bioresorbable magnesium stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magmaris</intervention_name>
    <description>Implantation of a sirolimus eluting bioresorbable magnesium stent</description>
    <arm_group_label>Magmaris</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable angina pectoris

          -  Stabilized non-ST elevation myocardial infarction

          -  Silent angina pectoris

          -  Age &gt; 18 years

          -  De novo coronary bifurcation lesion at LAD/diagonal, CX/obtuse marginal or
             RCA-PDA/posterolateral branch

          -  All Medina classes except Medina x.x.1.

          -  Diameter of side branch ≥ 2.5 mm

          -  Side branch diameter stenosis less than 50%

          -  Signed informed consent

        Exclusion Criteria:

          -  ST-elevation infarction within 48 hours

          -  Expected survival &lt; 1 year

          -  Severe heart failure (NYHA≥III)

          -  S-creatinine &gt; 120 µmol/L or GFR &lt; 0.45 mL/min per 1.73 m2

          -  Allergy to contrast media, aspirin, clopidogrel, ticagrelor, ticlopidine or sirolimus

          -  Unable to cover main vessel lesion with one stent

          -  Severe tortuosity

          -  Severe calcification
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evald H Christiansen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evald H Christiansen, MD, PhD</last_name>
    <phone>+4578452254</phone>
    <email>evald.christiansen@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Niels R Holm, MD</last_name>
    <phone>+45782254</phone>
    <email>niels.holm@clin.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels R Holm, MD</last_name>
      <phone>+45 7845 0000</phone>
      <phone_ext>52254</phone_ext>
      <email>niels.holm@clin.au.dk</email>
    </contact>
    <contact_backup>
      <last_name>Evald H Christiansen, MD</last_name>
      <phone>+45 7845 0000</phone>
      <phone_ext>52028</phone_ext>
      <email>hellbarg@rm.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>January 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2017</study_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital Skejby</investigator_affiliation>
    <investigator_full_name>Evald Hoej Christiansen</investigator_full_name>
    <investigator_title>Principal investigator (MD, PhD)</investigator_title>
  </responsible_party>
  <keyword>Percutaneous intervention (PCI)</keyword>
  <keyword>Optical coherence tomography (OCT)</keyword>
  <keyword>Bifurcation lesion</keyword>
  <keyword>Bioresorbable stents (BRS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

